Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.05 | -$0.05 | -$0.05 |
Q2 2024 | 1 | -$0.63 | -$0.63 | -$0.63 |
Q3 2024 | 1 | -$0.62 | -$0.62 | -$0.62 |
Q4 2024 | 1 | -$0.60 | -$0.60 | -$0.60 |
Q1 2025 | 1 | -$0.61 | -$0.61 | -$0.61 |
Q2 2025 | 1 | -$0.54 | -$0.54 | -$0.54 |
Q3 2025 | 1 | -$0.51 | -$0.51 | -$0.51 |
Q4 2025 | 1 | -$0.47 | -$0.47 | -$0.47 |
CASI Pharmaceuticals, Inc. last posted its earnings results on Friday, November 15th, 2024. The company reported $-0.55 earnings per share for the quarter, topping analysts' consensus estimates of $-0.62 by $0.07. The company had revenue of 7.79 M for the quarter and had revenue of 33.88 M for the year. CASI Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-2.02 diluted earnings per share) and currently has a price-to-earnings ratio of -1.34. CASI Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
09/30/2024 | Q3 2024 | -$0.55 | $4.56 M | $7.79 M | ||
06/28/2024 | Q2 2024 | -$0.52 | $4.43 M | $3.98 M | ||
03/29/2024 | Q1 2024 | -$0.71 | $3.41 M | |||
03/28/2024 | Q4 2023 | -$0.24 | -$0.41 | -0.17 | $6.09 M | |
09/29/2023 | Q3 2023 | -$0.35 | $10.43 M | $8.84 M | ||
06/29/2023 | Q2 2023 | -$0.77 | $10.09 M | $9.82 M | ||
03/30/2023 | Q1 2023 | -$0.45 | $8.35 M | |||
04/26/2023 | Q4 2022 | -$0.64 | -$1.37 | -0.73 | $15.26 M | |
11/14/2022 | Q3 2022 | -$0.51 | -$0.28 | 0.23 | $9.91 M | $10.21 M |
08/12/2022 | Q2 2022 | -$0.65 | -$0.56 | 0.09 | $7.87 M | $8.57 M |
05/12/2022 | Q1 2022 | -$1.00 | -$0.70 | 0.3 | $9.06 M | |
03/28/2022 | Q4 2021 | -$0.60 | -$0.04 | 0.56 | $9.16 M | |
11/12/2021 | Q3 2021 | -$0.60 | -$0.73 | -0.13 | $7.53 M | $8.11 M |
08/12/2021 | Q2 2021 | -$0.50 | $6.02 M | $7.16 M | ||
05/13/2021 | Q1 2021 | -$0.50 | -$1.11 | -0.61 | $5.74 M | |
03/30/2021 | Q4 2020 | -$0.70 | -$0.12 | 0.58 | $4.82 M | |
11/09/2020 | Q3 2020 | -$0.60 | -$1.44 | -0.84 | $3.44 M | $4.24 M |
08/10/2020 | Q2 2020 | -$0.80 | -$0.86 | -0.06 | $3.75 M | $2.67 M |
05/11/2020 | Q1 2020 | -$1.10 | -$0.85 | 0.25 | $3.41 M | |
03/16/2020 | Q4 2019 | -$1.10 | -$0.13 | 0.97 | $1.34 M |
CASI Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based off last year's report dates.
In the previous quarter, CASI Pharmaceuticals, Inc. (:CASI) reported $-0.55 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.62 by $0.07.
The conference call for CASI Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for CASI Pharmaceuticals, Inc.'s latest earnings report can be read online.
CASI Pharmaceuticals, Inc. (:CASI) has a recorded annual revenue of $33.88 M.
CASI Pharmaceuticals, Inc. (:CASI) has a recorded net income of $33.88 M. CASI Pharmaceuticals, Inc. has generated $-2.02 earnings per share over the last four quarters.
CASI Pharmaceuticals, Inc. (:CASI) has a price-to-earnings ratio of -1.34 and price/earnings-to-growth ratio is 0.13.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED